drugset / Trial / NCT05326464
Tofacitinib in Recurrent GBM Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Timeline
- Start
- 2022-10-07
- Primary completion
- 2025-02-18
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tofacitinib | Small molecule | 10 mg | Oral |
| Background | Lomustine | Small molecule | 90 mg/m2 | — |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |